Anti malarial drug ‘ARH 1’ launch by Lincoln Pharma

The Ahmedabad-based pharma firm Lincoln Pharmaceuticals (LPL) has launched anti-malarial drug ‘ARH 1’, developed using innovative technology known as Dose Optimization Technology under the Novel Drug Delivery System (NDDS). While mainstay treatment for malaria is complex and difficult to administer, ARH 1 is simpler and much more yielding making it easier for malarial patients to tolerate and recuperate from this disease. ARH 1 will be particularly helpful for the treatment of severe malaria, Falciparum. The drug is more effective with less volume, less pain and low viscosity providing better compliance to malarial patients. The company has applied for a patent of ‘ARH 1’ in India as well as internationally.

Millions of people fall victim to malaria in India every year, out of which 50 per cent of the cases are Falciparum Malaria; the most dangerous and life threatening form of malaria. ARH 1 will be available in injection form making it the Drug of Choice for the treatment of Malaria. ARH 1 contains Arteether 150mg/ml (Arteether is a fast acting blood schizonticidal agent that kills malarial parasite) and is manufactured using an innovative solubility technique which gives patients suffering from malaria the desired results. The launch of the ARH 1 injection will provide better treatment to millions of Indian’s suffering from the disease.

LPL conducted multi-centric trials on the efficacy and safety of the new and innovative ARH 1 injection at leading hospitals across the country. Clinical trials on more than 280 patients have proven the efficacy of this product in comparison to leading brands available in the market.